Halozyme Therapeutics
Country
USA
Краткое название
Halozyme Therapeutics
Headquarters
11388 Sorrento Valley Road
Members of the board
Gregory I. Frost , Ph.D. — President, Chief Executive Officer
Kurt A. Gustafson — Vice President, Chief Financial Officer
James P. Shaffer, MBA — Vice President, Chief Commercial Officer
H. Michael Shepard, Ph.D. — Vice President, Chief Scientific Officer
William J. Fallon — Vice President, Manufacturing & Operations
Don A. Kennard — Vice President, Regulatory Affairs & Quality Assurance
Michael J. LaBarre, Ph.D. — Vice President, Product Development
Jean I. Liu , M.S., J.D. — Vice President, General Counsel
Douglas B. Muchmore , M.D. — Vice President, Endocrinology Clinical Development
Joy Zhu , M.D., Ph.D — Vice President, Oncology Clinical Development
Kurt A. Gustafson — Vice President, Chief Financial Officer
James P. Shaffer, MBA — Vice President, Chief Commercial Officer
H. Michael Shepard, Ph.D. — Vice President, Chief Scientific Officer
William J. Fallon — Vice President, Manufacturing & Operations
Don A. Kennard — Vice President, Regulatory Affairs & Quality Assurance
Michael J. LaBarre, Ph.D. — Vice President, Product Development
Jean I. Liu , M.S., J.D. — Vice President, General Counsel
Douglas B. Muchmore , M.D. — Vice President, Endocrinology Clinical Development
Joy Zhu , M.D., Ph.D — Vice President, Oncology Clinical Development
Categories medicine
Endocrinology
Stage of the project
Production
Disease
Diabetes
Ticker
HALO
Current owners
Robert L. Engler , M.D.
Kathryn E. Falberg
Gregory I. Frost , Ph.D.
Kenneth J. Kelley , Chairman of the Board of Directors
Randal J. Kirk
Connie L. Matsui John S. Patton , Ph.D.
Kathryn E. Falberg
Gregory I. Frost , Ph.D.
Kenneth J. Kelley , Chairman of the Board of Directors
Randal J. Kirk
Connie L. Matsui John S. Patton , Ph.D.
Assets
2.5900
Technology
Cell Technologies, Homogeneous antibodies, Devices, Technologies, Pharmaceuticals, Chemistry